Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer - Related Studies

Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer

This study is currently recruiting participants.

Study NCT00623064. Last updated on October 1, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Bladder Cancer

2	Additional conditions recognized in this trial
		Carcinoma, Transitional Cell
		Kidney Neoplasms
		Ureteral Neoplasms
		Urinary Bladder Neoplasms

3	More general conditions related to this trial
		Carcinoma
		Kidney Diseases
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Glandular and Epithelial
		Ureteral Diseases
		Urinary Bladder Diseases
		Urogenital Neoplasms
		Urologic Diseases
		Urologic Neoplasms

4	Interventions listed in this trial
		cisplatin
		gemcitabine hydrochloride
		lapatinib ditosylate
		pharmacological study

5	Additional drug interventions recognized in this trial
		Gemcitabine
		Lapatinib

6	More general drug interventions related to this trial
		Anti-Infective Agents
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Antiviral Agents
		Enzyme Inhibitors
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Protein Kinase Inhibitors
		Radiation-Sensitizing Agents
		Therapeutic Uses

7	Sponsors listed in this trial
		European Organization for Research and Treatment of Cancer